Russell Investments Group Ltd. Acquires 4,711 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Russell Investments Group Ltd. lifted its position in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 2.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 215,712 shares of the company's stock after buying an additional 4,711 shares during the period. Russell Investments Group Ltd. owned approximately 0.17% of Henry Schein worth $14,927,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Dynamic Technology Lab Private Ltd bought a new stake in Henry Schein in the fourth quarter worth about $760,000. Resona Asset Management Co. Ltd. bought a new stake in shares of Henry Schein in the 4th quarter worth approximately $2,556,000. Riverwater Partners LLC raised its holdings in shares of Henry Schein by 7.6% in the 4th quarter. Riverwater Partners LLC now owns 5,140 shares of the company's stock worth $356,000 after purchasing an additional 365 shares in the last quarter. Atlas Capital Advisors Inc. acquired a new stake in Henry Schein during the fourth quarter valued at approximately $138,000. Finally, Huntington National Bank boosted its holdings in Henry Schein by 23.2% during the fourth quarter. Huntington National Bank now owns 1,866 shares of the company's stock worth $129,000 after buying an additional 351 shares in the last quarter. Institutional investors own 96.62% of the company's stock.

Henry Schein Stock Down 0.3 %

Shares of NASDAQ:HSIC traded down $0.19 during trading on Wednesday, reaching $64.09. 223,105 shares of the company traded hands, compared to its average volume of 1,603,078. The firm has a fifty day simple moving average of $71.27 and a 200 day simple moving average of $72.13. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. Henry Schein, Inc. has a 1-year low of $60.49 and a 1-year high of $82.49. The firm has a market cap of $7.96 billion, a P/E ratio of 26.37, a price-to-earnings-growth ratio of 2.13 and a beta of 0.84.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.23 by ($0.04). Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The firm had revenue of $3.19 billion during the quarter, compared to analysts' expectations of $3.25 billion. During the same quarter last year, the firm earned $0.66 EPS. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. Analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Insider Activity at Henry Schein

In other news, CEO Bradford C. Connett sold 4,036 shares of the firm's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the transaction, the chief executive officer now owns 62,688 shares in the company, valued at approximately $4,460,251.20. This trade represents a 6.05 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Philip A. Laskawy sold 2,604 shares of the company's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total transaction of $184,988.16. Following the completion of the sale, the director now owns 24,805 shares of the company's stock, valued at $1,762,147.20. This represents a 9.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.14% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on HSIC. StockNews.com raised Henry Schein from a "hold" rating to a "buy" rating in a research note on Wednesday, April 9th. Jefferies Financial Group boosted their price objective on Henry Schein from $77.00 to $80.00 and gave the stock a "hold" rating in a report on Thursday, January 23rd. Barrington Research reissued an "outperform" rating and issued a $90.00 target price on shares of Henry Schein in a research report on Wednesday, February 26th. Bank of America upgraded shares of Henry Schein from an "underperform" rating to a "buy" rating and upped their price target for the company from $69.00 to $84.00 in a research report on Monday, January 6th. Finally, UBS Group decreased their price objective on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a research note on Wednesday, February 26th. Five equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $81.10.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.